Iran on Monday opened a factory to mass produce its first domestically-made coronavirus vaccine COVIran Barekat.
Head of the Headquarters for Executing the Order of Imam, Mohammad Mokhber, said the first phase of plant, located in Alborz Province, is capable of producing three million doses of the jab per month.
Mokhber said with the second phase coming online in early May, the production capacity is expected to reach 12 million to 15 million doses monthly.
He made the comments in a ceremony to carry out the last-stage clinical trials of the shot in Tehran.
The CEO said phase 1 human trials of COVIran, conducted in late December on 56 volunteers, have showed successful results.
“The vaccine has been officially approved by competent authorities and proved to be 100 percent safe,” Mokhber said.
COVIran Barekat was named after Barekat Foundation, the executive subsidiary of the headquarters that has developed it.
Iranian scientists have been working on developing another domestic vaccine against the coronavirus, which is also in the human trial phase.
The second COVID-19 vaccine is a product of the Razi Vaccine and Serum Research Institute. Razi COV-Pars — an mRNA recombinant vaccine — is administered via injection and inhalation, Press TV wrote.
According to Mokhber, phase 2 and phase 3 will see 300 and 20,000 people respectively receiving the domestically produced COVIran Barekat vaccine for trials in Tehran and other provinces.
In parallel with efforts to develop homemade vaccines, Iran has purchased vaccines from Russia, China and India.
Officials say Iran will receive around 16 million doses of vaccines through the World Health Organization's COVAX program, import more than 25 million doses from abroad, and produce 25 million other doses inside the country.